Prime Medicine (NYSE:PRME – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, earnings, dividends, analyst recommendations and institutional ownership.
Valuation and Earnings
This table compares Prime Medicine and Pluri”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Prime Medicine | $2.98 million | 54.52 | -$198.13 million | ($1.65) | -0.75 |
| Pluri | $678,000.00 | 40.51 | -$20.89 million | ($5.60) | -0.70 |
Pluri has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Prime Medicine | 0 | 0 | 8 | 1 | 3.11 |
| Pluri | 0 | 0 | 0 | 0 | 0.00 |
Prime Medicine presently has a consensus target price of $13.38, indicating a potential upside of 978.63%. Given Prime Medicine’s stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Pluri.
Profitability
This table compares Prime Medicine and Pluri’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Prime Medicine | N/A | -107.87% | -74.97% |
| Pluri | -3,551.49% | -2,778.13% | -83.61% |
Risk & Volatility
Prime Medicine has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Pluri has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500.
Insider & Institutional Ownership
70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 23.5% of Prime Medicine shares are held by insiders. Comparatively, 10.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Prime Medicine beats Pluri on 13 of the 15 factors compared between the two stocks.
About Prime Medicine
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
About Pluri
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
